Sildenafil Citrate for Treatment of Growth-restricted Fetuses

Sildenafil Citrate for Treatment of Growth-restricted Fetuses

The aim of this study is to assess the effect of Sildenafil citrate therapy on neonatal outcomes in women with fetal growth restriction.

Inclusion Criteria:

• Maternal age ranging from 20-40 years.
• Gestational age 28-37 weeks.

Exclusion Criteria:

• Obese patients (BMI >30 kg/m2).
• Patients with medical disorders: cardiac diseases, pulmonary diseases, liver disease, renal disease, previous history of seizures, hearing loss.
• Drug interactions, such as users of any vasodilator agents, omeprazole, clarithromycin and amoxicillin.
• Fetal distress.
• Pregnancy of multiple fetuses.
• Congenital fetal malformation or chromosomal abnormalities.
• Diastolic blood pressure more than 110 mmHg.
• Hypersensitivity to the drug.